Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. develops therapies for severe neurodegenerative diseases, led by PrimeC, a proprietary fixed-dose oral extended-release combination of ciprofloxacin and celecoxib. Company news centers on PrimeC clinical and biomarker data in amyotrophic lateral sclerosis, Alzheimer’s disease program updates, regulatory interactions, and scientific publications or conference presentations related to the PARADIGM and PARAGON programs.
Recurring developments also include intellectual-property coverage for the PrimeC composition, including patent grants in Brazil, the United States and Australia, as well as Nasdaq listing compliance notices, shareholder voting matters, capital-structure disclosures, governance updates, material agreements, and operating or financial results.
NeuroSense (NASDAQ:NRSN) will participate in a Roth Capital Partners KOL webinar titled “A Quest to Outrun ALS” on July 8, 2026, at 11:00 a.m. ET.
Experts will discuss ALS treatment needs, trial endpoints, and NeuroSense’s PrimeC and its Phase 3 PARAGON study.
NeuroSense (NASDAQ:NRSN) reported that its Phase 2b PARADIGM study of PrimeC in ALS met the primary endpoint, showing a statistically significant reduction in neuron-derived TDP-43 versus placebo at Day 180 (p=0.0421), sustained and greater at Day 540 (p<0.001).
According to NeuroSense, PARADIGM also showed statistically significant slowing of ALSFRS-R decline at 12 and 18 months (36.5%, p=0.008; 32.8%, p=0.007), an estimated ~15‑month median survival benefit (HR 0.35, p=0.004), multi-biomarker target engagement, and a favorable safety profile. The company has FDA clearance to initiate its global Phase 3 PARAGON trial.
NeuroSense (NASDAQ:NRSN) reported positive biomarker findings from its Phase 2, randomized, double-blind, placebo-controlled RoAD proof-of-concept study of PrimeC in Alzheimer's disease. Eight participants were enrolled; three completed 12-month follow-up with CSF and plasma sampling at three timepoints.
PrimeC was associated with changes in key AD biomarkers (brain-derived tau, phospho-tau, amyloid-beta 42/40 ratio), misfolded proteins (alpha-synuclein, TDP-43), and markers of oxidative stress and inflammation, consistent with its proposed mechanism. No serious adverse events or new safety signals were identified. NeuroSense plans a future, adequately powered study informed by these data.
NeuroSense Therapeutics (NASDAQ:NRSN) announced that patient community group EverythingALS will host an online event titled “PrimeC - Connecting the Dots” on June 24, 2026, at 7 pm ET.
The session will review emerging data on PrimeC for ALS, led by Prof. Jeffrey Rosenfeld, joined by NeuroSense CEO Alon Ben-Noon, and is aimed at people with ALS, families, caregivers, clinicians, and others interested in ALS research.
NeuroSense (NASDAQ:NRSN) received South Korean Patent No. 10-2969898 covering the composition of PrimeC, its lead ALS candidate. The patent protects formulation, manufacturing process, pharmacokinetics and ALS use in South Korea through 2042.
This grant follows patents in Japan, Brazil, Australia and the US and supports plans to initiate the pivotal Phase 3 PARAGON ALS study, after Phase 2b PARADIGM results that, according to NeuroSense, showed slowed disease progression, biomarker activity and survival benefit.
NeuroSense Therapeutics (NASDAQ: NRSN) received Japanese Patent 7857044 for PrimeC, its lead ALS drug candidate, extending composition and formulation protection in Japan through 2042, subject to standard terms and potential extensions.
The patent covers PrimeC’s unique synchronized delivery of celecoxib and ciprofloxacin, supports a long-term commercialization strategy in a key market, and complements recent U.S., Australia, and Brazil patents. PrimeC is designed to modulate neuroinflammation, iron dysregulation, autophagy, and miRNA pathways, and showed clinical, biomarker, and survival benefits in the Phase 2b PARADIGM study. NeuroSense has FDA clearance and is preparing the pivotal Phase 3 PARAGON trial.
NeuroSense (NASDAQ: NRSN) announced a definitive agreement for a $600,000 insider-led private placement of 750,000 ordinary shares at $0.80 per share, a price 6.7% above the April 27, 2026 close. The offering includes $200,000 commitments each from CEO Alon Ben-Noon, CFO Or Eisenberg, and a significant existing shareholder. The private placement is expected to close during the week of May 3, 2026, is subject to customary closing conditions, and proceeds will be used for general corporate purposes ahead of upcoming clinical and regulatory milestones.
NeuroSense (NASDAQ: NRSN) announced that Brazil’s INPI granted Patent No. BR 112024007727-6 for its PrimeC composition, providing protection through October 2042. The grant follows corresponding U.S. (12,097,185) and Australian (2022370513) patents, strengthening the company’s global IP estate.
PrimeC is a fixed-dose oral combination of ciprofloxacin and celecoxib in an extended-release formulation. NeuroSense is preparing to initiate a Phase 3 pivotal PARAGON trial in ALS after positive Phase 2b PARADIGM results and FDA clearance, supporting longer-term development and potential commercialization.
NeuroSense (Nasdaq: NRSN) received Nasdaq notification letters on April 2, 2026, for noncompliance with the $1.00 minimum bid rule and the $35M minimum market value of listed securities (MVLS) rule after 30 consecutive business days below each threshold.
These notices do not affect current listing or trading. The company has until September 29, 2026 (180 days) to regain compliance by meeting each metric for 10 consecutive business days and is evaluating actions to restore compliance focused on long-term shareholder value.
NeuroSense (Nasdaq: NRSN) reported 2025 results and a business update. PrimeC advanced to a late-stage asset with FDA clearance to start the Phase 3 PARAGON trial and Phase 2b PARADIGM showed ~33% slowing of progression over 18 months.
In early 2026 the company reported a 65% reduction in risk of death and a >14-month median survival benefit; results were published in JAMA Neurology. Financials show $0.2M cash at Dec 31, 2025 and a $11.125M net loss for 2025. Key near-term milestones include a May 2026 pre-NDS meeting in Canada and Alzheimer’s readouts.